Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.75 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322695 | 0.92 | HDAC6 (0.74) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL8111683 | 0.91 | HDAC6 (0.62) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL8119245 | 0.90 | HDAC6 (0.60) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5329493 | 0.89 | HDAC6 (0.71) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5329490 | 0.89 | HDAC6 (0.71) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5323235 | 0.89 | HDAC6 (0.60) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5328257 | 0.89 | HDAC6 (0.68) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5329310 | 0.88 | HDAC6 (0.59) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5328630 | 0.87 | HDAC6 (0.70) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL5328621 | 0.87 | HDAC6 (0.70) | HDAC6HDAC1HDAC4HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | HDAC6 11/4885HDAC1 1/4885HDAC4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.